javascript hit counter
Business, Financial News, U.S and International Breaking News

NewsWorldpress is officially available on Google Play

Israeli firm's COVID-19 drug exhibits promise in late-stage coronavirus therapy

FIRST ON FOX: An Israeli public firm says it developed the “solely treatment for late-stage COVID” and mentioned that the outcomes of its part II medical trial, disclosed first to Fox Information, revealed that sufferers affected by extreme circumstances of COVID-19 had a 94% survival price after being handled with the drug. 

Israeli biotechnology firm Bonus BioGroup’s cell remedy MesenCure was administered to 50 hospitalized COVID-19 sufferers affected by life-threatening pneumonia and respiratory misery, the corporate mentioned, noting that 47 of these sufferers had survived. 

“These are essentially the most clinically significant outcomes offered immediately for treating extreme COVID-19 sufferers,” Dr. Tomer Bronshtein, the top of analysis at Bonus BioGroup Ltd., informed Fox Information in an unique interview. 

Bronshtein mentioned the part II medical trial, which just lately concluded and passed off in a number of medical facilities in Israel, revealed that MesenCure can “save three out of 4 individuals which can be prone to dying” and “can scale back their hospital size of keep by half.” He mentioned it “will speed up their therapeutic in a means that can trigger much less everlasting tissue harm and scale back the chance for ‘lengthy COVID.’” 

Israeli biotechnology company Bonus BioGroup’s cell therapy MesenCure 

Israeli biotechnology firm Bonus BioGroup’s cell remedy MesenCure  (Bonus BioGroup)

The corporate famous that for every of the primary 30 individuals within the medical trial, two sufferers, additionally affected by extreme circumstances, with comparable ages and comorbidities, have been chosen to the “management group,” which didn’t obtain MesenCure.

After analyzing the information, the corporate discovered that Mesencure diminished about 70% of extreme COVID-19 sufferers’ mortality in comparison with the mortality within the group that didn’t obtain the drug. The corporate additionally famous that about half of the sufferers with extreme circumstances of COVID-19 who have been handled with the remedy have been discharged from the hospital as much as simply in the future after the top of the therapy. 


“MesenCure is a drug constituted of dwelling cells,” Bronshtein defined, noting that the cells “are infused into the affected person” and as soon as the cells “attain their lungs, they fill the irritation and begin secreting molecules and compounds that soothe this irritation.”

The MesenCure study found that nearly all COVID-19 patients taking the drug survived.

The MesenCure research discovered that almost all COVID-19 sufferers taking the drug survived. (iStock, File)

Bronshtein famous that it additionally reduces pneumonia and edema, which helps sufferers “be capable of breathe.” 

“In parallel, [the cells] additionally ameliorate what’s referred to as the cytokine storm, which is the hyperimmune response that’s aggravated in COVID 19,” he added.  

Bonus BioGroup argued that it’s “essential to supply a therapeutic possibility for hospitalized, extreme COVID-19 sufferers” given “vaccines scale back, however don’t solely stop COVID-19 an infection and extreme sickness, which can be the case with drugs designed for at-home therapy of delicate COVID-19 that will scale back, however not stop hospitalization and extreme sickness.”


“We now have a drug that works and we need to put it to good use,” Bronshtein informed Fox Information, including that presently MesenCure is barely accessible to COVID-19 sufferers affected by extreme circumstances by compassionate use in Israel. 

Bonus BioGroup has been seeking emergency use approval for the drug in Israel.

Bonus BioGroup has been in search of emergency use approval for the drug in Israel. (iStock, File)

The Jerusalem Submit reported in August that the Well being Ministry had accepted the expanded use of MesenCure, which helped 15 out of the 17 sufferers with extreme circumstances of COVID-19 be launched from an Israeli hospital in the future after receiving their last dose.

Following the outcomes of the part II medical trial, Bronshtein mentioned Bonus BioGroup is now in search of emergency use approval beginning in Israel. The corporate can be persevering with to run part III research. 


“We hope that after we get the approval in Israel, it is going to be accepted extra simply in america and in Europe,” Bronshtein informed Fox Information.

Bonus BioGroup CEO Shai Meretzki informed Fox Information he was “very blissful that in lower than 18 months we have been capable of develop a brand new accessible remedy for all these extreme sufferers that so far didn’t have an answer.” 

This text was initially revealed by Learn the authentic article right here.

Comments are closed.

NewsWorldpress officially on Google Play